COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02927080
Recruitment Status : Terminated (Investigation of ACE-083 for use in patients with FSHD is being discontinued as it did not achieve functional secondary endpoints in the A083-02 trial.)
First Posted : October 6, 2016
Last Update Posted : November 6, 2019
Information provided by (Responsible Party):
Acceleron Pharma, Inc.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : September 17, 2019
Actual Study Completion Date : October 9, 2019